`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Paper No. ___
`Date Filed: July 16, 2019
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`WOCKHARDT BIO AG,
`
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner
`________________
`
`Case IPR2016-01582
`________________
`
`Patent No. 8,822,438 B2
`
`
`
`PATENT OWNER’S MOTION TO EXPUNGE
`UNDER 37 C.F.R. § 42.56
`
`
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`I.
`
`STATEMENT OF RELIEF REQUESTED
`
`Pursuant to 37 C.F.R. § 42.56 and the Board’s email authorization of July
`
`16, 2019, Patent Owner Janssen Oncology, Inc. (“Patent Owner”) respectfully
`
`requests that, for the reasons set forth below, the Board expunge from the record:
`
`1) Paper Nos. 12, 26, and Paper 28 and Exhibits 2002, 2003, which reflect business
`
`confidential communications between the parties; and 2) Exhibits 1089, 1103,
`
`2044, 2092, 2093, 2118 and 2161, which contain Patent Owner’s confidential
`
`information. Patent Owner certifies that the parties have conferred in good faith,
`
`and Petitioner does not oppose this motion.
`
`II.
`
`PROCEDURAL BACKGROUND
`
`On November 16, 2016, December 22, 2016, and March 17, 2017, Patent
`
`Owner filed motions to seal Papers 12 and 26 (which are the confidential versions
`
`of redacted Papers 13 and 27, respectively),1 Exhibits 2002, 2003, 2044, and 2161
`
`(which are the confidential versions of redacted Exhibits 2005, 2004, 2115, and
`
`2162, respectively), and Exhibits 2092, 2093, and 2118 (which are confidential in
`
`their entirety). See Paper 11, 25, and 41. On April 19, 2017, Petitioner filed a
`
`motion to seal Exhibits 1089 and 1103 (which are the confidential versions of
`
`redacted Exhibits 1121 and 1122, respectively). See Paper 52.
`
`
`1 On January 19, 2017, the Board issued the institution decision under seal (Paper
`
`28) along with a corresponding public version (Paper 29).
`
`
`
`1
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`
`Paper 12, Paper 26, and Exhibits 2002 and 2003 reflect the parties’
`
`confidential communications that addressed Patent Owner’s assertion that
`
`Petitioner did not properly identify all real parties-in-interest. Exhibits 1089, 1103,
`
`2044, 2092, 2093, 2118, and 2161 contain Patent Owner’s confidential
`
`information. In the Final Written Decision, the Board granted Patent Owner’s and
`
`Petitioner’s motions to seal. See Paper No. 72 at 47-49. Furthermore, the Board
`
`found that “[i]n rendering [its] Final Written Decision, it was not necessary to
`
`identify, nor discuss in detail, any confidential information.” Id. at 48. The Board
`
`ordered that the exhibits and papers remain under seal until “the time period for
`
`filing a notice of appeal has expired or, if an appeal is taken, the appeal process has
`
`concluded.” Id. at 49.
`
`On December 19, 2018, Patent Owner filed a Notice of Appeal. Paper 77.
`
`On May 14, 2019, the United States Court of Appeals for the Federal Circuit (the
`
`“Federal Circuit”) issued its opinion and judgment, and on June 20, 2019, the
`
`Federal Circuit issued its mandate.
`
`III. APPLICABLE LEGAL STANDARDS
`
`37 C.F.R. § 42.56 provides that “[a]fter denial of a petition to institute a trial or
`
`after final judgment in a trial, a party may file a motion to expunge confidential
`
`information from the record.” The Board has previously explained that a party
`
`moving to expunge has to show that: i) “any information sought to be expunged
`
`
`
`2
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`constitutes confidential information[;]” and ii) the movant’s interest in expunging
`
`the information “outweighs the public’s interest in maintaining a complete and
`
`understandable file history.” RPX Corp. v. VirnetX Inc., IPR 2014-00171, Paper 62
`
`at 3 (P.T.A.B. Sept. 9, 2014). The regulations identify confidential information as
`
`“a trade secret or other confidential research, development, or commercial
`
`information.” 37 C.F.R. § 42.54(a)(7). The Board must strike “a balance between
`
`the public’s interest in maintaining a complete and understandable file history and
`
`the parties’ interest in protecting truly sensitive information.” 77 Fed. Reg. 48756,
`
`48760 (Aug. 14, 2012).
`
`IV. REASONS FOR THE RELIEF REQUESTED
`
`In its Final Written Decision, the Board stated that “confidential information
`
`that is subject to a protective order ordinarily would become public 45 days after
`
`final judgment in a trial, unless a motion to expunge is granted.” Paper 72 at 48.
`
`Accordingly, Patent Owner moves to expunge from the record the following sealed
`
`papers and exhibits reflecting the parties’ confidential communications or
`
`containing Patent Owner’s confidential information:
`
` Papers and exhibits concerning Petitioner’s disclosure of real parties-in-
`
`interest: Patent Owner’s Preliminary response, Paper 12 (filed November
`
`16, 2016); Patent Owner’s Surreply to Patent Owner Preliminary
`
`Response, Paper 26 (filed December 22, 2016); Exhibit 2002 (filed
`
`
`
`3
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`
`November 16, 2016); Exhibit 2003 (filed November 16, 2016);
`
`Institution Decision, Paper 28 (entered January 19, 2017).
`
` Internal, non-public research summaries concerning the use of Patent
`
`Owner’s product: Exhibit 2092 (filed March 17, 2017); Exhibit 2093
`
`(filed March 17, 2017);
`
` Internal, non-public technical research and development information
`
`concerning Patent Owner’s product: Exhibit 2118 (filed March 17,
`
`2017).
`
` Expert declarations and deposition transcripts referring to Patent Owner’s
`
`confidential information: Deposition of Richard J. Auchus, M.D., Ph.D.,
`
`Exhibit 1089 (filed April 19, 2017); Reply Declaration of Robert B.
`
`Stoner, Ph.D., Exhibit 1103 (filed April 19, 2017); Declaration of
`
`Christopher A. Vellturo, Ph.D., Exhibit 2044 (filed March 17, 2017);
`
`Deposition transcript of Paul A. Godley, M.D., Ph.D., MPP, Exhibit 2161
`
`(filed March 17, 2017).
`
`The parties have already demonstrated, and the Board agreed, that Papers
`
`12, 26, and 28, and Exhibits 1089, 1103, 2002, 2003, 2044, 2092, 2093, 2118, and
`
`2161 contain confidential information. Paper 72 at 48; Paper 29. There has been no
`
`change in confidentiality of the information contained in these papers and exhibits.
`
`Thus, the parties have met their burden of showing that “any information sought to
`
`
`
`4
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`be expunged constitutes confidential information.” RPX, IPR2014-00171, Paper 62
`
`at 3.
`
`In addition, the parties’ interest in expunging the parties’ confidential
`
`business communications (in Papers 12, 26, and 28, and Exhibits 2002 and 2003)
`
`and Patent Owner’s interest in expunging the confidential information in Exhibits
`
`1089, 1103, 2044, 2092, 2093, 2118, and 2161 “outweigh[s] the public’s interest in
`
`maintaining a complete and understandable file history.” Id. As stated in its Final
`
`Written Decision, the Board did not “identify, nor discuss in detail” the
`
`confidential information when rendering its decision. Paper 72 at 48.
`
`Although the Board’s institution decision discussed Papers 12 and 26, and
`
`Exhibits 2002 and 2003, the analysis did not concern the patentability of the
`
`challenged claims, but the identification of real parties-in-interest. See Google
`
`LLC v. Seven Networks, LLC, IPR2018-01048, Paper 38 at 3 (P.T.A.B. Mar. 29,
`
`2019) (finding good cause exists to expunge confidential versions of papers,
`
`exhibits, and the institution decision that concern real party-in-interest and privity
`
`issues, but are not relevant to the merits of the case); Jiawei Tech. Ltd. v.
`
`Richmond, IPR2014-00935, Paper 71 at 3 (P.T.A.B. Jul. 23, 2018) (finding that
`
`“consideration of the [subject exhibits] was not necessary for the panel’s
`
`determination of whether the challenged claims of the challenged patent were
`
`
`
`5
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`shown to be unpatentable, but rather only to [the Board’s] determination of
`
`whether [petitioner] had properly identified all real parties in interest”).
`
`The public, therefore, has access to all the materials relevant to the merits of
`
`this proceeding, either through publicly filed papers and exhibits or through
`
`redacted, public versions of Paper 12 (Paper 13), Paper 26 (Paper 27), Paper 28
`
`(Paper 29), Exhibit 2002 (Exhibit 2005), Exhibit 2003 (Exhibit 2004), Exhibit
`
`2044 (Declaration of Christopher A. Vellturo, Ph.D. - Exhibit 2115), Exhibit 2161
`
`(Deposition transcript of Paul A. Godley, M.D., Ph.D., MPP - Exhibit 2162),
`
`Exhibit 1089 (Deposition Transcript of Richard J. Auchus, M.D., Ph.D. - Exhibit
`
`1121), and Exhibit 1103 (Reply Declaration of Robert B. Stoner, Ph.D. - Exhibit
`
`1122). Given the confidential nature of the information in Papers 12, 26, and 28, as
`
`well as Exhibits 1089, 1103, 2002, 2003, 2044, 2092, 2093, 2118, and 2161, good
`
`cause exists for the Board to expunge these papers and exhibits pursuant to 37
`
`C.F.R. § 42.56.
`
`V. CONCLUSION
`
`For the reasons set forth above, Patent Owner requests that the Board grant
`
`this motion and expunge Paper Nos. 12, 26, and 28, as well as Exhibits 1089, 1103,
`
`2002, 2003, 2044, 2092, 2093, 2118 and 2161 from the record.
`
`
`
`
`
`
`
`6
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`July 16, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER &
`FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel: (215) 965-1200
`Fax: (215) 965-1210
`JANS-ZYTIGA@akingump.com
`
`David T. Pritikin (pro hac vice)
`dpritikin@sidley.com
`Paul Zegger (Reg. No. 33,821)
`pzegger@sidley.com
`Alyssa B. Monsen (pro hac vice)
`amonsen@sidley.com
`SIDLEY AUSTIN LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 839-5300
`Fax: (212) 839-5599
`ZytigaIPRTeam@sidley.com
`
`Counsel for Patent Owner
`
`
`
`
`
`
`
`
`
`7
`
`
`
`Case: IPR2016-01582
`U.S. Patent No. 8,822,438
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Motion to Expunge Under 37 C.F.R. § 42.56 was served on counsel of
`
`record on July 16, 2019 by filing this document through the End-to-End System, as
`
`well as delivering a copy via electronic mail to counsel of record for the Petitioner
`
`and Patent Co-Owner at the following addresses:
`
`Dennies Varughese – dvarughe-PTAB@skgf.com
`Deborah A. Sterling – dsterlin-PTAB@skgf.com
`Lestin L. Kenton Jr. – lkenton-PTAB@skgf.com
`Ralph W. Powers III – tpowers-PTAB@skgf.com
`
`Anthony C. Tridico – anthony.tridico@finnegan.com
`Jennifer H. Roscetti – jennifer.roscetti@finnegan.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`(Reg. No. 28,598)
`
`Counsel for Patent Owner
`Janssen Oncology, Inc.
`
`8
`
`July 16, 2019
`
`
`
`
`
`
`
`
`
`
`
`